## CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

wherein:

$R_1$ is $C_{1-8}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{1-6}$ haloalkyl, wherein the $C_{1-8}$ alkyl, $C_{3-6}$ cycloalkyl and $C_{1-6}$ haloalkyl groups are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of $C_{1-6}$ acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, aryl, substituted aryl, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, heteroaryl, heterocyclyl, hydroxyl, nitro and thiol;

$R_2$, $R_3$ and $R_4$ are each independently selected from the group consisting of H, $C_{1-6}$ acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, hydroxyl, nitro and thiol; and

$R_5$ is H or $C_{1-6}$ alkyl; or

a pharmaceutically acceptable salt or a solvate thereof;

provided that:

a) when $R_5$ is ethyl, and $R_2$, $R_3$ and $R_4$ are H then $R_1$ is not methyl or triphenylmethyl;

b) when $R_5$ is n-pentyl, and $R_2$, $R_3$ and $R_4$ are H then $R_1$ is not n-butyl;

c) when $R_5$ is methyl, and $R_2$, $R_3$ and $R_4$ are H then $R_1$ is not pyrrolidin-1-ylmethyl, 3-tert-butyl-2-hydroxy-5-methyl-benzyl, methyl, or dimethylaminomethyl;

d) when $R_5$ is methyl, $R_2$ is carbomethoxy and $R_3$ and $R_4$ are both H then $R_1$ is not methyl;

e) when $R_2$, $R_3$, $R_4$ and $R_5$ are all H then $R_1$ is not 2-amino-2-carboxy-ethyl, pyrrolidin-1-ylmethyl, isopropyl, methyl, benzyl, n-butyl, or carboxymethyl; and

f) when $R_2$, $R_4$, and $R_5$ are all H and $R_3$ is methoxy then $R_1$ is not methyl.

2. A compound according to claim 1 wherein:

$R_1$ is $C_{3-6}$ cycloalkyl or $C_{1-6}$ haloalkyl, where each $C_{3-6}$ cycloalkyl or $C_{1-6}$ haloalkyl group is optionally substituted with 1, 2, 3, or 4 substituents selected form the group consisting of $C_{1-6}$acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, hydroxyl, nitro and thiol;

$R_2$, $R_3$ and $R_4$ are each independently selected from the group consisting of H, $C_{1-6}$ acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, hydroxyl, nitro or thiol; and

$R_5$ is H or $C_{1-6}$ alkyl; or a pharmaceutically acceptable salt or a solvate thereof.

3. The compound according to claim 1 or 2 wherein $R_5$ is $C_{1-6}$ alkyl.

4. The compound according to claim 1 or 2 wherein $R_5$ is H.

5. The compound according to any one of claims 1 to 4 wherein $R_2$, $R_3$ and $R_4$ are each independently H or halogen.

6. The compound according to any one of claims 1 to 4 wherein $R_2$, $R_3$ and $R_4$ are each independently H or F.

7. The compound according to any one of claims 1 and 3 to 6 wherein $R_1$ is $C_{1-8}$ alkyl optionally substituted with substituents selected from the group consisting of $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, aryl, substituted aryl, $C_{3-6}$ cycloalkyl, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, heteroaryl, heterocyclyl, and hydroxyl.

8. The compound according to any one of claims 1 and 3 to 6 wherein $R_1$ is selected from the group consisting of 2-butyl, 3-pentyl, 1-propyl, t-butyl, 1-butyl, 4-Methyl-pentyl, 3-methyl-butyl, 1,3-dimethyl-butyl, 3,3-dimethyl-butyl, 1-heptyl, ethyl, 2,2-dimethyl-propyl, and 1-pentyl.

9. The compound according to any one of claims 1 and 3 to 6 wherein $R_1$ is selected from the group consisting of 3-methoxy-benzyl, 4-methoxy-benzyl, 4-methoxy-phenyl ethyl, 3-methoxy-phenyl ethyl, 3,5-difluorobenzyl, and benzhydryl.

10. The compound according to any one of claims 1 and 3 to 6 wherein $R_1$ is selected from the group consisting of 3-isopropoxypropyl, tetrahydro-furan-2-ylmethyl, 2-methoxy-ethyl, 2-ethylsulfanyl-ethyl, 3-hydroxy-propyl, allyl, cyclopropylmethyl, but-2-ynyl, 2-methoxy-1-methyl-ethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2-ethoxy-ethyl, and 1,2-dimethyl-propyl.

11. The compound according to any one of claims 1 to 6 wherein $R_1$ is selected from the group consisting of cyclopentyl, cyclohexyl, cyclopropyl, and cyclobutyl.

12. The compound according to claim 1 selected from the group consisting of:

1-Cyclopentyl-1H-benzotriazole-5-carboxylic acid;
1-(2'-Butyl)-1H-benzotriazole-5-carboxylic acid;
1-(3'-Pentyl)-1H-benzotriazole-5-carboxylic acid;
1-Cyclohexyl-1H-benzotriazole-5-carboxylic acid
1-Propyl-1H-benzotriazole-5-carboxylic acid;
1-Cyclopropyl-1H-benzotriazole-5-carboxylic acid;
1-(3'-Isopropoxy-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(Tetrahydro-furan-2'-ylmethyl)-1H-benzotriazole-5-carboxylic acid;
1-Cyclobutyl-1H-benzotriazole-5-carboxylic acid;
1-(2-Methoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(3'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
1-(4'Methoxybenzyl)-1H-benzotriazole-5-carboxylic acid;
1-[2'-(4''-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;
1-[2'-(3''-Methoxy-phenyl)-ethylamino]-1H-benzotriazole-5-carboxylic acid;
1-(3',5'-Difluorobenzyl)-1H-benzotriazole-5-carboxylic acid;
1-(2-Ethylsulfanyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-t-Butyl-1H-benzotriazole-5-carboxylic acid;

1-(3'-Hydroxy-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(1',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
1-(3',3'-Dimethyl-butyl)-1H-benzotriazole-5-carboxylic acid;
1-Heptyl-1H-benzotriazole-5-carboxylic acid;
1-(2'-Methoxy-1'-methyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(2'-Hydroxy-1'-hydroxymethyl-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-Ethyl-1H-benzotriazole-5-carboxylic acid;
1-Pentyl-1H-benzotriazole-5-carboxylic acid;
1-(2',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-(2'-Ethoxy-ethyl)-1H-benzotriazole-5-carboxylic acid;
1-(1',2'-Dimethyl-propyl)-1H-benzotriazole-5-carboxylic acid;
1-Benzhydryl-1H-benzotriazole-5-carboxylic acid;
1-Allyl-1H-benzotriazole-5-carboxylic acid;
1-Butyl-1H-benzotriazole-5-carboxylic acid;
1-(Cyclopropylmethyl)-1H-benzotriazole-5-carboxylic acid;
1-(But-2-ynyl)-1H-benzotriazole-5-carboxylic acid;
1-(4'-Methyl-pentyl)-1H-benzotriazole-5-carboxylic acid; and
1-(3'-Methyl-butyl)-1H-benzotriazole-5-carboxylic acid; or
a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. A pharmaceutical composition comprising a compound according to:

a) Formula (I):



(I)

wherein:

$R_1$ is H, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{1-6}$ haloalkyl, wherein each $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl or $C_{1-6}$ haloalkyl group is optionally substituted with $C_{1-6}$ acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, hydroxyl, nitro or thiol;

$R_2$, $R_3$ and $R_4$ are independently H, $C_{1-6}$ acyl, $C_{1-6}$ acyloxy, $C_{2-6}$ alkenyl, $C_{1-6}$ alkoxy, $C_{1-6}$ alkyl, $C_{1-6}$ alkylcarboxamido, $C_{2-6}$ alkynyl, $C_{1-6}$ alkylsulfinyl, $C_{1-6}$ alkylsulfonyl, $C_{1-6}$ alkylthio, $C_{1-6}$ alkylureyl, amino, $C_{1-6}$ alkylamino, $C_{1-6}$ dialkylamino, carbo $C_{1-6}$ alkoxy, carboxy, cyano, $C_{3-6}$ cycloalkyl, $C_{1-6}$ dialkylcarboxamido, halogen, $C_{1-6}$ haloalkoxy, $C_{1-6}$ haloalkyl, $C_{1-6}$ haloalkylsulfinyl, $C_{1-6}$ haloalkylsulfonyl, $C_{1-6}$ haloalkylthio, hydroxyl, nitro or thiol; and

$R_5$ is H or $C_{1-6}$ alkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof; or

b) any one of claims 1 to 12; wherein said compound is in combination with a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 further comprising an agent selected from the group consisting of α-glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.

15. A compound according to any one of claims 1 to 12 for use in a method of treatment of the human or animal body by therapy.

16. A compound according to any one of claims 1 to 12 for use in a method of treatment of metabolic-related disorders.

17. A compound according to any one of claims 1 to 12 for use in a method of treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

18. A compound according to any one of claims 1 to 12 for use in a method of treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

19. A compound according to any one of claims 1 to 12 for use in a method of treatment of atherosclerosis.

20. A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 12.

21. A method according to claim 20 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

22. A method according to claim 20 wherein said metabolic-related disorder is atherosclerosis.

23. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder.

24. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

25. Use of a compound according to one of claims 1 to 12 for the manufacture of a medicament for use in the treatment of atherosclerosis.